Repligen Corporation (RGEN)

Market Closed

17 Aug, 20:00

NASDAQ (NGS)

169. 04

+2.21

+1.3247%

Pre Market

170. 00

+0.96 +0.5679%

9.42B Market Cap

212.35 P/E Ratio

- Div Yield

627,387 Volume

1.46 Eps

$ 166.83

Previous Close

Investors:

ABB

+85

Analysts:

Add Transaction

Day Range

164.94 169.5

Year Range

100.99 175.77

Want to track RGEN and more in your Portfolio? 🎯

Get Started For Free

Wall Street Analysts Believe Repligen (RGEN) Could Rally 25.72%: Here's is How to Trade

The consensus price target hints at a 25.7% upside potential for Repligen (RGEN). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Zacks | 2 weeks ago

Repligen Beats Q2 Earnings Estimates, Raises 2026 View, Stock Up

RGEN tops Q2 earnings and revenue estimates, lifts its 2026 revenue and EPS outlook, and sees shares jump after stronger-than-expected results.

Zacks | 2 weeks ago

Repligen Q2 Earnings Call Highlights

Repligen NASDAQ: RGEN reported second-quarter 2026 revenue of $204 million, up 12% year over year on a reported basis and 13% organically, as demand for proteins, analytics products and recurring consumables supported growth. The company also raised its full-year organic revenue growth and adjusted earnings outlook, citing continued order momentum and improved visibility into the second half.

Marketbeat | 2 weeks ago

Repligen (RGEN) Beats Q2 Earnings and Revenue Estimates

Repligen (RGEN) came out with quarterly earnings of $0.54 per share, beating the Zacks Consensus Estimate of $0.45 per share. This compares to earnings of $0.37 per share a year ago.

Zacks | 2 weeks ago

Repligen to Expand Cell Therapy Capabilities With BioLife Buyout

RGEN's $1.5 billion BioLife acquisition aims to expand its cell therapy capabilities, adding biopreservation products and expected revenue and EPS benefits.

Zacks | 3 weeks ago

Repligen Corporation (RGEN) M&A Call Transcript

Seekingalpha | 3 weeks ago

Repligen to Buy BioLife Solutions for $1.5 Billion, Expanding Cell Therapy Reach

Repligen NASDAQ: RGEN said it has signed a definitive agreement to acquire BioLife Solutions in a transaction valued at approximately $1.5 billion, adding a cell therapy-focused platform that management said will expand Repligen's exposure to one of the faster-growing areas of bioprocessing.

Marketbeat | 3 weeks ago